Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
610 · 2 trials · 1 indication
Annualized rate of severe exacerbation events during the 52-week placebo-controlled treatment period
FEV1 is defined as the volume of air expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry.
| Arm | Type | Description |
|---|---|---|
| 610 group | EXPERIMENTAL | Subjects will receive 610 for 52 weeks. |
| placebo group | PLACEBO_COMPARATOR | Subjects will receive placebo for 52 weeks. |
| Group A | EXPERIMENTAL | Subjects will receive 610 for 52 weeks. |
| Group B | EXPERIMENTAL | Subjects will receive 610 for 52 weeks. |
| Name | Type | Description |
|---|---|---|
| 610 | DRUG | 610 subcutaneously injection. |
| Placebo | DRUG | Placebo subcutaneously injection. |
Inclusion Criteria: 1. Able to give written informed consent prior to participation in the study. 2. Male or female adults ages 18 to 75 years old when signing the informed consent. 3. Documented diagnosis of asthma for at least one year prior to screening. 4. History of physician-diagnosed asthma ...
610 is an investigational small molecule being developed for the treatment of asthma, specifically severe asthma and severe eosinophilic asthma. It is currently in clinical development and has not been approved by regulatory authorities.
610 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SBFM. The company is conducting clinical trials for 610 in patients with asthma.
610 is in Phase 3 clinical development for severe asthma. A Phase 2b study in severe eosinophilic asthma is also active. The drug is investigational and has not received regulatory approval.
610 is being studied in two clinical trials: NCT06323213, a Phase 3 study in patients with severe asthma, and NCT06680947, a Phase 2b study in participants with severe eosinophilic asthma. Both trials are randomized, double-blind, and placebo-controlled.
610 is the code name for the investigational drug developed by Sunshine Biopharma Inc. No alternative names for 610 have been disclosed in the clinical trial information.